OptiBiotix Health PLC Exercise of warrant and issue of equity (9732D)
February 06 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 9732D
OptiBiotix Health PLC
06 February 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Exercise of warrant and issue of equity
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
has received a notification for the exercise of warrants over
800,000 ordinary shares in the Company at an exercise price of 8p
per share, providing the Company with proceeds of GBP64,000.
Application will be made to the London Stock Exchange to admit
the 800,000 new ordinary shares to trading on AIM. Admission of the
new ordinary shares is expected to occur on or around 9 February
2018. The new ordinary shares will rank pari passu with the
existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules,
following the issue of shares detailed above the enlarged issued
share capital of the Company will comprise 80,485,712 ordinary
shares of 2p each. The above figure may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company, under the Disclosure and
Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 and the person who arranged
for release of this announcement on behalf of the Company was Mark
Collingbourne, Chief Financial Officer.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap Broker Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEBRGDDSDGBGIU
(END) Dow Jones Newswires
February 06, 2018 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024